IFNA1 and COVID-19: A study by Monk et al. (2021) revealed that IFN therapy administered via inhalation resulted in a significantly higher recovery rate in patients with moderate-to-severe COVID-19 (RR = 1.72, 95% CI: 1.09–2.70) [16].